(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.45%) $83.47
(-1.16%) $1.619
(-0.01%) $2 347.00
(0.84%) $27.48
(0.35%) $925.30
(-0.05%) $0.934
(-0.15%) $11.01
(-0.07%) $0.800
(0.00%) $92.17
3 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 6.71%
2.23% $ 64.06
@ $64.15
Emitido: 26 abr 2024 @ 13:48
Retorno: -0.14%
Señal anterior: abr 25 - 15:50
Señal anterior:
Retorno: 2.40 %
Live Chart Being Loaded With Signals
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide...
Stats | |
---|---|
Volumen de hoy | 946 213 |
Volumen promedio | 1.09M |
Capitalización de mercado | 10.07B |
EPS | $0 ( 2024-02-01 ) |
Próxima fecha de ganancias | ( $0.460 ) 2024-05-01 |
Last Dividend | $0.0800 ( 2023-11-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 46.09 |
ATR14 | $1.869 (2.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-03 | Bohnen Shane | Sell | 2 259 | Restricted Stock Units |
2024-04-03 | Bohnen Shane | Buy | 2 259 | Common Stock |
2024-04-03 | Bohnen Shane | Sell | 747 | Common Stock |
2024-03-07 | Nusse Roeland | Sell | 10 400 | Common Stock |
2024-02-01 | Geist William | Sell | 1 111 | Common Stock |
INSIDER POWER |
---|
3.66 |
Last 99 transactions |
Buy: 1 979 464 | Sell: 2 067 622 |
Volumen Correlación
Bio-Techne Corp Correlación
10 Correlaciones Más Negativas | |
---|---|
SVAC | -0.935 |
TLGT | -0.901 |
RMRM | -0.897 |
PAIC | -0.887 |
FEYE | -0.864 |
SVOK | -0.851 |
TEAM | -0.842 |
UBOH | -0.834 |
TRIN | -0.833 |
INZY | -0.827 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Bio-Techne Corp Correlación - Moneda/Commodity
Bio-Techne Corp Finanzas
Annual | 2023 |
Ingresos: | $1.14B |
Beneficio Bruto: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2023 |
Ingresos: | $1.14B |
Beneficio Bruto: | $769.82M (67.72 %) |
EPS: | $1.810 |
FY | 2022 |
Ingresos: | $1.11B |
Beneficio Bruto: | $756.50M (68.42 %) |
EPS: | $1.730 |
FY | 2021 |
Ingresos: | $931.03M |
Beneficio Bruto: | $632.85M (67.97 %) |
EPS: | $0.867 |
Financial Reports:
No articles found.
Bio-Techne Corp Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0.0800 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0625 | 2008-10-30 |
Last Dividend | $0.0800 | 2023-11-09 |
Next Dividend | $0 | N/A |
Payout Date | 2023-11-24 | |
Next Payout Date | N/A | |
# dividends | 61 | -- |
Total Paid Out | $4.63 | -- |
Avg. Dividend % Per Year | 0.25% | -- |
Score | 4.89 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 6.04 | |
Div. Directional Score | 8.94 | -- |
Year | Amount | Yield |
---|---|---|
2008 | $0.0625 | 0.37% |
2009 | $0.253 | 1.57% |
2010 | $0.263 | 1.53% |
2011 | $0.273 | 1.64% |
2012 | $0.285 | 1.66% |
2013 | $0.303 | 1.75% |
2014 | $0.313 | 1.33% |
2015 | $0.320 | 1.40% |
2016 | $0.320 | 1.45% |
2017 | $0.320 | 1.25% |
2018 | $0.320 | 0.97% |
2019 | $0.320 | 0.90% |
2020 | $0.320 | 0.58% |
2021 | $0.320 | 0.41% |
2022 | $0.320 | 0.26% |
2023 | $0.320 | 0.39% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.196 | 1.500 | 6.08 | 9.13 | [0 - 0.5] |
returnOnAssetsTTM | 0.0821 | 1.200 | 7.26 | 8.72 | [0 - 0.3] |
returnOnEquityTTM | 0.115 | 1.500 | 9.84 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.225 | -1.000 | 7.75 | -7.75 | [0 - 1] |
currentRatioTTM | 4.37 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 2.54 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 0.962 | 1.500 | 5.77 | 8.65 | [0.2 - 2] |
debtRatioTTM | 0.203 | -1.500 | 6.61 | -9.91 | [0 - 0.6] |
interestCoverageTTM | 20.76 | 1.000 | 3.42 | 3.42 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.28 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.283 | -1.500 | 8.87 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.671 | 1.000 | 2.15 | 2.15 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.235 | 1.000 | 7.31 | 7.31 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.497 | 1.000 | 8.35 | 8.35 | [0.2 - 2] |
assetTurnoverTTM | 0.419 | 0.800 | -0.538 | -0.430 | [0.5 - 2] |
Total Score | 11.84 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 45.02 | 1.000 | 5.55 | 0 | [1 - 100] |
returnOnEquityTTM | 0.115 | 2.50 | 9.90 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.431 | 2.00 | 9.52 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.500 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.755 | 2.00 | 9.42 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.225 | 1.500 | 7.75 | -7.75 | [0 - 1] |
pegRatioTTM | 0.335 | 1.500 | -1.100 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.241 | 1.000 | 6.46 | 0 | [0.1 - 0.5] |
Total Score | 6.04 |
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico